

Parigi: May 17-20, 2016

Focus Innovation Hub

Planned and ongoing clinical trials: a status
update from Mediolanum Cardiovascular Research

Session evaluation and key learnings

Speaker - 10'

Antonio Colombo

*Centro Cuore Columbus and
S. Raffaele Scientific Institute, Milan, Italy*

No conflicts to disclose

Alessio Gargaro: Home Monitoring seems a very important tool able to predict worsening of Heart Failure, early detection may prompt more aggressive therapy avoiding hospitalization

Antonio Micari: There is a clear need to evaluate performance of DEB in SFA. Major strength: high risk population (over 50% diabetics), 251 mm lesion length, Peak Systolic Velocity Ratio, High % of Follow-up

Stefano Savonitto: Elderly Trial, very important to establish appropriate antiplatelet therapy in these patients. WE NEED THE RESULT!


Marco Mennuni: Unique Gender Study regarding LAA morphology

Gabriele Vicedomini: The value of Real Life Studies:

HAS-BLED 2.9; CHA2DS2-VASc 4.0

Diab8 randomized trial

Study design



PI: Antonio Colombo

Primary Endpoint: 12 months Target Lesion Failure (TLF) for **SUPERIORITY** of Cre8

Clinical FU

